Guardant Health, Inc (GH)

Etorro trading 970x250
Guardant Health, Inc (GH) Logo

About Guardant Health, Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Address: 505 Penobscot Drive, Redwood City, CA, United States, 94063

Guardant Health, Inc News and around…

Latest news about Guardant Health, Inc (GH) common stock and company :

Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
25 Oct, 2021 FinancialContent

Guardant Health, Inc. (Nasdaq: GH), presents data at the American College of Gastroenterology Annual Scientific Meeting being held from October 22-27, showing its LUNAR-2 blood test, which has been developed to screen average-risk patients for colorectal cancer (CRC), offers optimized sensitivity and specificity in identifying those with early-stage CRC. This study was selected by the ACG Abstract Selection Committee as the recipient of the International Award.

Guardant Health Appoints Myrtle Potter to Its Board of Directors
20 Oct, 2021 FinancialContent

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.

GH February 2022 Options Begin Trading
19 Oct, 2021 FinancialContent

Investors in Guardant Health Inc (GH) saw new options begin trading today, for the February 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 122 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

This investor crushes his fund’s benchmark with these 10 stocks
12 Oct, 2021 FinancialContent

Neal Kaufman at the Baron Health Care Fund seeks out companies with durable advantages and recurring revenue.

Guardant Health to Report Third Quarter Financial Results on November 4, 2021
08 Oct, 2021 FinancialContent

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
05 Oct, 2021 FinancialContent

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-patient prospective, observational, multi-center study designed to evaluate the performance of its Guardant Reveal™ liquid biopsy test to predict cancer recurrence after curative intent treatment, across 11 solid tumor types.

Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
04 Oct, 2021 FinancialContent

Guardant Health Inc(NASDAQ: GH) hasdecided not to pursue a potential acquisitionofNeoGenomics ...

Here is What Hedge Funds Think About Guardant Health, Inc. (GH)
04 Oct, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

54 Biggest Movers From Friday
04 Oct, 2021 FinancialContent

Check out these big penny stock gainers and losersLosers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to ...

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
03 Oct, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Noteworthy Friday Option Activity: CASH, W, GH
01 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Meta Financial Group Inc (CASH), where a total volume of 1,309 contracts has been traded thus far today, a contract volume which is representative of approximately 130,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 66.9% of CASH's average daily trading volume over the past month, of 195,710 shares..

Friday's ETF Movers: PEJ, BBH
01 Oct, 2021 FinancialContent

In trading on Friday, the Invesco Dynamic Leisure and Entertainment ETF is outperforming other ETFs, up about 3% on the day. Components of that ETF showing particular strength include shares of Tripadvisor, up about 8.4% and shares of Everi Holdings, up about 7.7% on the day.

Why Guardant Health Is Down More Than 14% Friday
01 Oct, 2021 FinancialContent

Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.

12 Health Care Stocks Moving In Friday's Intraday Session
01 Oct, 2021 FinancialContent

Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 ...

35 Stocks Moving In Friday's Mid-Day Session
01 Oct, 2021 Yahoo! Finance

Gainers Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system. Progenity, Inc. (NASDAQ: PROG) gained 23% to $1.87 after jumping over 40% on Thursday. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) climbed 21.3% to $42.52 following data from Merck & Co's investigational oral antiviral molnupiravir, which boosted sentiment for Atea Pharmaceutical's AT

Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
01 Oct, 2021 FinancialContent

Bloomberg reportedthatGuardant Health Inc(NASDAQ: GH) is reportedly exploring an acquisition ofNeoGenomics ...

Guardant Said to Weigh Deal For Diagnostics Firm NeoGenomics
01 Oct, 2021 Yahoo! Finance

(Bloomberg) -- Guardant Health Inc. is exploring an acquisition of cancer diagnostics and testing firm NeoGenomics Inc., according to people familiar with the matter. NeoGenomics rose more than 13% on the news. Most Read from BloombergWall Street Titans Warn of the Next Big Risks for InvestorsAn Unapologetic Old Boys’ Network Is Costing Australia BillionsThe Unstoppable Appeal of Highway ExpansionThe Country That Makes Breakfast for the World Is Plagued by Fire, Frost and DroughtReshaped by Cris

Investing in These 2 Top Stocks Could Make You a Millionaire Retiree
30 Sep, 2021 FinancialContent

Both of these companies boast exciting growth prospects.

SoftBank Vision Fund’s Deep Nishar to Leave at End of Year
27 Sep, 2021 Yahoo! Finance

(Bloomberg) -- SoftBank Vision Fund’s sole senior managing partner, Deep Nishar, is set to leave the firm by the end of the year.Most Read from BloombergReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoWall Street Titans Warn of the Next Big Risks for InvestorsAn Unapologetic Old Boys’ Network Is Costing Australia BillionsThis Is What Europe’s Green Future Looks LikeGhana’s Record Cocoa Harvest Is Bittersweet for Export IndustryNishar, who’s based in the San Francisco Bay Area, announced

First Week of November 19th Options Trading For Guardant Health (GH)
20 Sep, 2021 FinancialContent

Investors in Guardant Health Inc (GH) saw new options begin trading this week, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GH options chain for the new November 19th contracts and identified one put and one call contract of particular interest.

The 1 Stock I'd Buy Right Now
18 Sep, 2021 FinancialContent

The pandemic isn't over yet.

Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
15 Sep, 2021 FinancialContent

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.

3 Crash-Ready Stocks to Buy in September
14 Sep, 2021 FinancialContent

History says this month can be scary. These stocks can get you through it.

12 Health Care Stocks Moving In Friday's After-Market Session
10 Sep, 2021 FinancialContent

Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) shares rose 10.84% to $1.84 during Friday's after-market session. Hepion ...

How The Parts Add Up: XHS Headed For $134
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Services ETF (XHS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $134.27 per unit.

SoftBank Vision Fund’s Deep Nishar Is Discussing Leaving Firm
08 Sep, 2021 Yahoo! Finance

(Bloomberg) -- SoftBank Vision Fund’s sole senior managing partner, Deep Nishar, is discussing leaving the firm, according to people with knowledge of the matter.Nishar, who’s based in the San Francisco Bay Area, joined SoftBank in 2015, according to his LinkedIn profile. Previously a lecturer at Stanford University, he also served as a senior vice president of products and user experience at LinkedIn, and before that, worked at Google. Nishar also has a strong technical background, co-authoring

New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
07 Sep, 2021 FinancialContent
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
02 Sep, 2021 FinancialContent
GH Makes Bullish Cross Above Critical Moving Average
02 Sep, 2021 FinancialContent

In trading on Thursday, shares of Guardant Health Inc (GH) crossed above their 200 day moving average of $133.11, changing hands as high as $133.33 per share. Guardant Health Inc shares are currently trading up about 1.4% on the day..

Return on Capital Employed Insights for Guardant Health
01 Sep, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Guardant Health's (NASDAQ:GH) reported sales totaled $92.10 million. ...

Guardant Health, Inc (GH) is a NASDAQ Common Stock listed in , ,